{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:40:05Z","timestamp":1785516005655,"version":"3.56.0"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2011,12,20]],"date-time":"2011-12-20T00:00:00Z","timestamp":1324339200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0028124","type":"journal-article","created":{"date-parts":[[2011,12,20]],"date-time":"2011-12-20T21:52:07Z","timestamp":1324417927000},"page":"e28124","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":59,"title":["Statin-Associated Muscular and Renal Adverse Events: Data Mining of the Public Version of the FDA Adverse Event Reporting System"],"prefix":"10.1371","volume":"6","author":[{"given":"Toshiyuki","family":"Sakaeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Kadoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Okuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,12,20]]},"reference":[{"key":"ref1","first-page":"CD004816","article-title":"Statins for the primary prevention of cardiovascular disease.","volume":"1","author":"F Taylor","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.2165\/10898610-000000000-00000","article-title":"Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-lowering drugs.","volume":"70","author":"PP Toth","year":"2010","journal-title":"Drugs"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s11883-010-0120-9","article-title":"Evidence-based management of statin myopathy.","volume":"12","author":"CR Harper","year":"2010","journal-title":"Curr Atheroscler Rep"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.2522\/ptj.20090251","article-title":"Effects of statins on skeletal muscle: a perspective for physical therapists.","volume":"90","author":"SL Di Stasi","year":"2010","journal-title":"Phys Ther"},{"key":"ref5","first-page":"843","article-title":"Benefits of statin therapy and compliance in high risk cardiovascular patients.","volume":"6","author":"JA Lardizabal","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2710.2009.01085.x","article-title":"A systematic review and meta-analysis on the therapeutic equivalence of statins.","volume":"35","author":"TC Weng","year":"2010","journal-title":"J Clin Pharm Ther"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.amjcard.2009.08.651","article-title":"Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).","volume":"105","author":"SJ Nicholls","year":"2010","journal-title":"Am J Cardiol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(03)14669-7","article-title":"The statin wars: why AstraZeneca must retreat.","volume":"362","year":"2003","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(03)14698-3","article-title":"The statin wars.","volume":"362","author":"T McKillop","year":"2003","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/S0140-6736(04)16513-6","article-title":"Dangers of rosuvastatin identified before and after FDA approval.","volume":"363","author":"SM Wolfe","year":"2004","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(04)16616-6","article-title":"Safety and efficacy of rosuvastatin.","volume":"364","author":"GO Olsson","year":"2004","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(04)17301-7","article-title":"Should rosuvastatin be withdrawn from the market?","volume":"364","author":"SR Florentinus","year":"2004","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/S0140-6736(04)17302-9","article-title":"Should rosuvastatin be withdrawn from the market?","volume":"364","author":"JJ Kastelein","year":"2004","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0140-6736(04)17304-2","article-title":"Should rosuvastatin be withdrawn from the market?","volume":"364","author":"JS Cohen","year":"2004","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1016\/S0140-6736(04)17525-9","article-title":"Rosuvastatin and the statin wars-the way to peace.","volume":"364","author":"RH Meyboom","year":"2004","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1056\/NEJMp058029","article-title":"Safety in numbers-monitoring risk in approved drugs.","volume":"352","author":"S Okie","year":"2005","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1161\/CIRCULATIONAHA.105.555482","article-title":"The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis.","volume":"111","author":"AA Alsheikh-Ali","year":"2005","journal-title":"Circulation"},{"key":"ref18","first-page":"73","article-title":"Rosuvastatin: an independent analysis of risks and benefits.","volume":"8","author":"DP Zipes","year":"2006","journal-title":"Med Gen Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.","volume":"10","author":"SJ Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions.","volume":"11","author":"EP van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation.","volume":"54","author":"A Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database.","volume":"25","author":"A Szarfman","year":"2002","journal-title":"Drug Saf"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting.","volume":"18","author":"A Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/pds.771","article-title":"Practical pharmacovigilance analysis strategies.","volume":"12","author":"AL Gould","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.clpt.6100258","article-title":"Novel statistical tools for monitoring the safety of marketed drugs.","volume":"82","author":"JS Almenoff","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2013the PRIMO study.","volume":"19","author":"E Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3949\/ccjm.78a.10073","article-title":"Statin myopathy: a common dilemma not reflected in clinical trials.","volume":"78","author":"G Fernandez","year":"2011","journal-title":"Cleve Clin J Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"C1208","DOI":"10.1152\/ajpcell.00226.2006","article-title":"Statin-induced apoptosis and skeletal myopathy.","volume":"291","author":"AJ Dirks","year":"2006","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00002018-200730080-00003","article-title":"Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance.","volume":"30","author":"BA Golomb","year":"2007","journal-title":"Drug Saf"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/jcp.2003.012989","article-title":"The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.","volume":"57","author":"VG Athyros","year":"2004","journal-title":"J Clin Pathol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2215\/CJN.04371206","article-title":"Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.","volume":"2","author":"J Shepherd","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1053\/j.ajkd.2009.03.022","article-title":"Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).","volume":"54","author":"HM Colhoun","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1053\/j.ajkd.2008.11.025","article-title":"Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.","volume":"53","author":"MJ Koren","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1161\/01.CIR.0000032466.44170.44","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins.","volume":"106","author":"RC Pasternak","year":"2002","journal-title":"Circulation"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/ptj\/85.5.459","article-title":"Potential adverse effects of statins on muscle.","volume":"85","author":"SS Tomlinson","year":"2005","journal-title":"Phys Ther"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1212\/WNL.0b013e31820c3648","article-title":"Myopathy: five new things.","volume":"76","author":"B Oskarsson","year":"2011","journal-title":"Neurology"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0028124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T01:41:16Z","timestamp":1593394876000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0028124"}},"subtitle":[],"editor":[{"given":"James M.","family":"Wright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,12,20]]},"references-count":36,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2011,12,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0028124","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,20]]}}}